Literature DB >> 8359193

Pharmacokinetics of exogenous adenosine in man after infusion.

P Blardi1, F Laghi Pasini, R Urso, C Frigerio, L Volpi, L De Giorgi, T Di Perri.   

Abstract

The plasma kinetics of adenosine was investigated in healthy volunteers after a 1 minute infusion of 2.5, 5 and 10 mg (38.79 and 148 micrograms.kg-1 respectively) and after infusion of 200 micrograms.kg-1 in 10 min followed by 400 micrograms.kg-1 in 10 min. As the dose in the 1 min infusion study was increased the mean CL of adenosine decreased (10.7, 4.70 and 4.14 l.min-1, respectively), its mean half-life increased (0.91, 1.24 and 1.86 min, respectively), and the mean volume of distribution did not show any clear trend (8-13 l). After the 20 minute infusion the plasma level of adenosine reached a peak value comparable to that observed after infusion of 5 mg in 1 min (about 0.5 micrograms.ml-1), but the mean clearance and half-life were significantly different (12.1 l.min-1 and 0.63 min respectively). In all the subjects the plasma concentration of adenosine had returned to the baseline value in 5-15 min after the end of the infusion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359193     DOI: 10.1007/bf00315554

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  4 in total

Review 1.  Adenosine. An evaluation of its use in cardiac diagnostic procedures, and in the treatment of paroxysmal supraventricular tachycardia.

Authors:  D Faulds; P Chrisp; M M Buckley
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

2.  Turnover of adenosine in plasma of human and dog blood.

Authors:  G H Möser; J Schrader; A Deussen
Journal:  Am J Physiol       Date:  1989-04

3.  Haemodynamic and metabolic effects of infused adenosine in man.

Authors:  A Edlund; A Sollevi; B Linde
Journal:  Clin Sci (Lond)       Date:  1990-08       Impact factor: 6.124

4.  Dipyridamole inhibition of adenosine metabolism in human blood.

Authors:  R E Klabunde
Journal:  Eur J Pharmacol       Date:  1983-09-16       Impact factor: 4.432

  4 in total
  6 in total

1.  Pharmacokinetics and tolerability of intravenous infusion of adenosine (SUNY4001) in healthy volunteers.

Authors:  T Uematsu; O Kozawa; H Matsuno; M Niwa; H Yoshikoshi; M Oh-uchi; K Kohno; S Nagashima; M Kanamaru
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

2.  Extracellular cAMP: The Past and Visiting the Future in cAMP-Enriched Extracellular Vesicles.

Authors:  Aritra Bhadra; Jenny L Hewes; April Scruggs; Chun Zhou; Ji Young Lee; Natalie Bauer
Journal:  Adv Biol (Weinh)       Date:  2021-10-28

3.  Adenosine kinase is a new therapeutic target to prevent ischemic neuronal death.

Authors:  Detlev Boison; Hai-Ying Shen
Journal:  Open Drug Discov J       Date:  2010-01-01

4.  Physiology and effects of nucleosides in mice lacking all four adenosine receptors.

Authors:  Cuiying Xiao; Naili Liu; Kenneth A Jacobson; Oksana Gavrilova; Marc L Reitman
Journal:  PLoS Biol       Date:  2019-03-01       Impact factor: 8.029

5.  The ischemic preconditioning effect of adenosine in patients with ischemic heart disease.

Authors:  Bita Sadigh; Miguel Quintana; Christer Sylvén; Margareta Berglund; Lars Ake Brodin
Journal:  Cardiovasc Ultrasound       Date:  2009-11-05       Impact factor: 2.062

Review 6.  Adenosine-Related Mechanisms in Non-Adenosine Receptor Drugs.

Authors:  Kenneth A Jacobson; Marc L Reitman
Journal:  Cells       Date:  2020-04-13       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.